Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Mallinckrodt
Daiichi Sankyo
Baxter
Fish and Richardson
Boehringer Ingelheim
US Army
Fuji
Express Scripts

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090718

« Back to Dashboard

NDA 090718 describes MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, which is a drug marketed by Chartwell Rx, Glenmark Pharms, Heritage Pharms Inc, and Teva, and is included in four NDAs. It is available from four suppliers. Additional details are available on the MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE profile page.

The generic ingredient in MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; moexipril hydrochloride. There are thirty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; moexipril hydrochloride profile page.
Summary for 090718
Pharmacology for NDA: 090718
Ingredient-typeThiazides
Mechanism of ActionAngiotensin-converting Enzyme Inhibitors
Physiological EffectIncreased Diuresis
Suppliers and Packaging for NDA: 090718
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 090718 ANDA Glenmark Pharmaceuticals Inc., USA 68462-205 N 68462-205-01
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 090718 ANDA Glenmark Pharmaceuticals Inc., USA 68462-205 N 68462-205-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG;7.5MG
Approval Date:Mar 17, 2010TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG;15MG
Approval Date:Mar 17, 2010TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG;15MG
Approval Date:Mar 17, 2010TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
US Department of Justice
Dow
Moodys
Chinese Patent Office
QuintilesIMS
Healthtrust
Boehringer Ingelheim
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.